ARN-509 (BioDeep_00000784454)
代谢物信息卡片
Apalutamide
化学式: C21H15F4N5O2S (477.0882538)
中文名称: 阿帕他胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CNC(=O)C1=C(C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(N=C4)C#N)C(F)(F)F)F
InChI: InChI=1S/C21H15F4N5O2S/c1-27-17(31)13-4-3-11(8-15(13)22)30-19(33)29(18(32)20(30)5-2-6-20)12-7-14(21(23,24)25)16(9-26)28-10-12/h3-4,7-8,10H,2,5-6H2,1H3,(H,27,31)
描述信息
L - Antineoplastic and immunomodulating agents > L02 - Endocrine therapy > L02B - Hormone antagonists and related agents > L02BB - Anti-androgens
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C146993 - Androgen Receptor Inhibitor
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C242 - Anti-Androgen
同义名列表
2 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- KEGGdrug: D11040
- PubChem: 24872560
- DrugBank: DB11901
- ChEMBL: CHEMBL3183409
- CAS: 956104-40-8
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Alex Yu, Maura Erba, Anasuya Hazra. Pharmacokinetics and Use-Testing of Apalutamide Prepared in Aqueous Food Vehicles for Alternative Administration.
Clinical pharmacology in drug development.
2021 11; 10(11):1375-1384. doi:
10.1002/cpdd.1001. [PMID: 34273257] - Mathieu Roumiguié, Xavier Paoletti, Yann Neuzillet, Romain Mathieu, Sebastien Vincendeau, François Kleinclauss, Arnaud Mejean, Laurent Guy, Marc Olivier Timsit, Thierry Lebret. Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Future oncology (London, England).
2021 May; 17(14):1811-1823. doi:
10.2217/fon-2020-1104. [PMID: 33543650] - Hiroji Uemura, Yosuke Koroki, Yuki Iwaki, Keiichiro Imanaka, Takeshi Kambara, Angela Lopez-Gitlitz, Andressa Smith, Hirotsugu Uemura. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
BMC urology.
2020 Sep; 20(1):139. doi:
10.1186/s12894-020-00689-0. [PMID: 32878613] - Ignacio Duran, Joan Carles, Iurie Bulat, Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, Danielle Armas, Caly Chien. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer.
Clinical pharmacokinetics.
2020 09; 59(9):1135-1148. doi:
10.1007/s40262-020-00882-2. [PMID: 32338345] - An Van den Bergh, Jan Snoeys, Loeckie De Zwart, Peter Ward, Angela Lopez-Gitlitz, Daniele Ouellet, Mario Monshouwer, Caly Chien. Pharmacokinetic Drug-Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model.
Clinical pharmacokinetics.
2020 09; 59(9):1149-1160. doi:
10.1007/s40262-020-00881-3. [PMID: 32338346] - Carlos Pérez-Ruixo, Jonás Samuel Pérez-Blanco, Caly Chien, Margaret Yu, Daniele Ouellet, Juan-José Pérez-Ruixo, Oliver Ackaert. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Clinical pharmacokinetics.
2020 02; 59(2):229-244. doi:
10.1007/s40262-019-00808-7. [PMID: 31432469] - Changhua Ji, Mausumee Guha, Xu Zhu, Jessica Whritenour, Michelle Hemkens, Susanna Tse, Gregory S Walker, Ellen Evans, Nasir K Khan, Martin B Finkelstein, Ernesto Callegari, R Scott Obach. Enzalutamide and Apalutamide: In Vitro Chemical Reactivity Studies and Activity in a Mouse Drug Allergy Model.
Chemical research in toxicology.
2020 01; 33(1):211-222. doi:
10.1021/acs.chemrestox.9b00247. [PMID: 31538772] - Tomohiro Tsuchiya, Keiichiro Imanaka, Yuki Iwaki, Ryo Oyama, Katsuyoshi Hashine, Akito Yamaguchi, Hiroji Uemura. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
International journal of clinical oncology.
2019 Dec; 24(12):1596-1604. doi:
10.1007/s10147-019-01526-7. [PMID: 31446511] - Ronald de Vries, Frank Jacobs, Geert Mannens, Jan Snoeys, Filip Cuyckens, Caly Chien, Peter Ward. Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes.
Drug metabolism and disposition: the biological fate of chemicals.
2019 05; 47(5):453-464. doi:
10.1124/dmd.118.084517. [PMID: 30787101] - Neil R Parikh, Claudia Huiza, Jill S Patel, Sonny Tsai, Nathisha Kalpage, May Thein, Sage Pitcher, Steve P Lee, Warren S Inouye, Mark L Jordan, Homayoon Sanati, Lida Jafari, Carol J Bennett, Greg E Gin, Amar U Kishan, Robert E Reiter, Michael Lewis, Ahmad Sadeghi, William J Aronson, Isla P Garraway, Matthew B Rettig, Nicholas G Nickols. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
BMC cancer.
2019 Apr; 19(1):291. doi:
10.1186/s12885-019-5496-5. [PMID: 30935383] - Bodine P S I Belderbos, Ronald de Wit, Caly Chien, Anna Mitselos, Peter Hellemans, James Jiao, Margaret K Yu, Gerhardt Attard, Iurie Bulat, W Jeffrey Edenfield, Fred Saad. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology.
2018 09; 82(3):457-468. doi:
10.1007/s00280-018-3632-6. [PMID: 29974203] - Gurulingappa Hallur, Buchi Reddy Purra, Suresh P Sulochana, Neeraj Kumar Saini, Prasanthi Daram, Mohd Zainuddin, Ramesh Mullangi. Validation of an LC-ESI-MS/MS method for the determination of apalutamide, a novel non-steroidal anti-androgen in mice plasma and its application to a pharmacokinetic study in mice.
Journal of pharmaceutical and biomedical analysis.
2018 May; 153(?):260-266. doi:
10.1016/j.jpba.2018.02.054. [PMID: 29518645] - Lorenzo Tosco, Annouschka Laenen, Thomas Gevaert, Isabelle Salmon, Christine Decaestecker, Elai Davicioni, Christine Buerki, Frank Claessens, Johan Swinnen, Karolien Goffin, Raymond Oyen, Wouter Everaerts, Lisa Moris, Gert De Meerleer, Karin Haustermans, Steven Joniau. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
BMC cancer.
2018 04; 18(1):354. doi:
10.1186/s12885-018-4275-z. [PMID: 29606109] - Xuehai Pang, Yingwei Wang, Yuanwei Chen. Design, synthesis, and biological evaluation of deuterated apalutamide with improved pharmacokinetic profiles.
Bioorganic & medicinal chemistry letters.
2017 06; 27(12):2803-2806. doi:
10.1016/j.bmcl.2017.04.071. [PMID: 28478926] - Eva Gupta, Troy Guthrie, Winston Tan. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
BMC urology.
2014 Jul; 14(?):55. doi:
10.1186/1471-2490-14-55. [PMID: 25062956] - James D Joseph, Nhin Lu, Jing Qian, John Sensintaffar, Gang Shao, Dan Brigham, Michael Moon, Edna Chow Maneval, Isan Chen, Beatrice Darimont, Jeffrey H Hager. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.
Cancer discovery.
2013 Sep; 3(9):1020-9. doi:
10.1158/2159-8290.cd-13-0226. [PMID: 23779130] - Dana Rathkopf, Howard I Scher. Androgen receptor antagonists in castration-resistant prostate cancer.
Cancer journal (Sudbury, Mass.).
2013 Jan; 19(1):43-9. doi:
10.1097/ppo.0b013e318282635a. [PMID: 23337756] - Nicola J Clegg, John Wongvipat, James D Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D Bischoff, Ling Cai, Anna Aparicio, Steven Dorow, Vivek Arora, Gang Shao, Jing Qian, Hong Zhao, Guangbin Yang, Chunyan Cao, John Sensintaffar, Teresa Wasielewska, Mark R Herbert, Celine Bonnefous, Beatrice Darimont, Howard I Scher, Peter Smith-Jones, Mark Klang, Nicholas D Smith, Elisa De Stanchina, Nian Wu, Ouathek Ouerfelli, Peter J Rix, Richard A Heyman, Michael E Jung, Charles L Sawyers, Jeffrey H Hager. ARN-509: a novel antiandrogen for prostate cancer treatment.
Cancer research.
2012 Mar; 72(6):1494-503. doi:
10.1158/0008-5472.can-11-3948. [PMID: 22266222]